Takeda’s Specialty Biz Unit Most Likely to Handle GI Meds, Entyvio Launch Apparently Eyed

Masato Iwasaki, President, Japan Pharma Business Unit, Takeda Pharmaceutical While Takeda Pharmaceutical was mum about the specifics of the Specialty Business Unit when its April launch was announced on February 16, gastroenterology drugs are the most likely portfolio that would...read more